TY - JOUR AU - Wang, Zhe AU - Chen, Lin AU - Rao, Wei AU - Cao, Baoshan AU - Cai, Muyan AU - Fan, Xiangshan AU - Ji, Yuan AU - Li, Yuan AU - Song, Yan AU - Sun, Yan AU - Sun, Yu AU - Wu, Chunyan AU - Xia, Qingxin AU - Xi, Yanfeng AU - Xue, Liyan AU - Yin, Rutie AU - Liang, Han AU - Ying, Jianming PY - 2026 TI - Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor JO - Cancer Innovation SN - 2770-9191 SP - e70060 VL - 5 IS - 2 AB - Human epidermal growth factor receptor 2 (HER2) is a key biomarker and therapeutic target in several malignancies, including breast, gastric, and other solid tumors. Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2‐positive pan‐tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers. However, the lack of standardized guidelines for HER2 testing in a pan‐tumor context creates variability in clinical practice, hindering the optimal implementation of HER2‐targeted therapies beyond traditional indications. To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies. UR - https://doi.org/10.1002/cai2.70060 DO - 10.1002/cai2.70060